FIELD: chemistry.
SUBSTANCE: present invention relates to antisense oligonucleotides, modulating expression of pancreatic developmental gene, in particular, by targeted interaction with natural antisense polynucleotides of pancreatic developmental gene. Said oligonucleotides have a length from 15 to 30 nucleotides, have a sequence at least 90 % identical to sequence, inverse to complementary section from 1 to 1 235 nucleotide sequence SEQ ID SEQ ID NO: 6, from 1 to 17 964 nucleotide sequence SEQ ID NO: 7, from 1 to 50 003 nucleotide sequence SEQ ID SEQ ID NO: 8, from 1 to 486 nucleotide sequence SEQ ID NO: 9, from 1 to 494 nucleotide sequence SEQ ID NO: 10, from 1 to 1 992 nucleotide sequence SEQ ID NO: 11, or from 1 to 1 767 nucleotide sequence SEQ ID NO: 12, or have a sequence, at least 90 % identical to section of sequence selected from SEQ ID NOS: 1-5, and are specifically hybridised with natural antisense polynucleotide, selected from SEQ ID NOS: 6-12, wherein said oligonucleotides can optionally contain one or more modifications, selected from following: at least one modified sugar fragment, at least one modified inter-nucleoside bond, at least one modified nucleotide and combination thereof. Present invention also relates to use of such antisense oligonucleotides for treating diseases and disorders, associated with expression of pancreatic developmental genes.
EFFECT: invention widens range of products for treating diseases and disorders associated with expression of pancreatic developmental genes.
31 cl, 5 dwg, 1 tbl, 2 ex
